04:32 PM EDT, 07/02/2025 (MT Newswires) -- Dyadic International ( DYAI ) said Wednesday it will begin doing business as Dyadic Applied BioSolutions in 30 days, reflecting its shift from a research-driven organization to a commercially focused enterprise.

The company said it will continue advancing legacy collaborations, including one with the Gates Foundation, where it recently reached milestones that triggered a second $1.5 million installment from a $3 million non-dilutive grant to develop low-cost monoclonal antibodies for diseases such as malaria and RSV.

The company's shares were rising past 1% in after-hours activity.